PMID- 35920868
OWN - NLM
STAT- MEDLINE
DCOM- 20220830
LR  - 20220830
IS  - 2167-9436 (Electronic)
IS  - 2167-9436 (Linking)
VI  - 41
IP  - 4
DP  - 2022 Aug
TI  - Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for 
      Outpatient Treatment of SARS-CoV-2 in a Real-World Setting.
PG  - 210-213
LID - 10.1089/mab.2022.0008 [doi]
AB  - Monoclonal antibody (mAb) therapy has emerged as one of the mainstay treatment 
      options for SARS-CoV-2. To improve speed of delivery and decrease bedside nursing 
      needs, subcutaneous (SC) delivery of mAbs has been explored as an alternative to 
      standard intravenous (IV) administration. To date, data regarding the 
      effectiveness of SC compared with IV mAb are lacking. This retrospective cohort 
      analysis conducted between April 2021 and August 2021 compared hospitalization 
      rates among patients receiving IV versus SC administration of 
      casirivimab/imdevimab (Regen-COV) at a single institution in Arkansas. 
      Casirivimab/imdevimab was a promising mAb therapy utilized during the height of 
      the Delta variant surge of the SARS-CoV-2 pandemic. Before resistance developed 
      by the Omicron variant, casirivimab/imdevimab was utilized for outpatient 
      treatment of SARS-CoV-2 patients at risk of deterioration. Primary outcomes of 
      this investigation were the 30-day post-treatment rate of hospitalization and 
      intensive care unit (ICU) care during hospitalization. There was no increased 
      risk of hospitalization or ICU care with SC administration compared with IV 
      administration. As SARS-CoV-2 continues to mutate into variants such as Omicron 
      and develop resistance to existing mAbs, these preliminary findings of 
      noninferiority of SC versus IV warrant ongoing investigation into SC 
      administration of other mAbs.
FAU - Belote, Alex
AU  - Belote A
AUID- ORCID: 0000-0002-8247-6007
AD  - Department of Internal Medicine, University of Arkansas for Medical Sciences 
      Northwest, Fayetteville, Arkansas, USA.
FAU - Reece, Sharon
AU  - Reece S
AD  - Department of Family and Preventive Medicine, University of Arkansas for Medical 
      Sciences Northwest, Fayetteville, Arkansas, USA.
FAU - Robinson, Samantha
AU  - Robinson S
AD  - Department of Mathematical Sciences, University of Arkansas, Fayetteville, 
      Arkansas, USA.
FAU - Jensen, Hanna
AU  - Jensen H
AD  - Department of Surgery, University of Arkansas for Medical Sciences, Little Rock, 
      Arkansas, USA.
FAU - CarlLee, Sheena
AU  - CarlLee S
AD  - Department of Internal Medicine, University of Arkansas for Medical Sciences 
      Northwest, Fayetteville, Arkansas, USA.
FAU - Clark, Megan
AU  - Clark M
AD  - College of Medicine, University of Arkansas for Medical Sciences Northwest, 
      Fayetteville, Arkansas, USA.
FAU - Parnell, Spencer
AU  - Parnell S
AD  - College of Medicine, University of Arkansas for Medical Sciences Northwest, 
      Fayetteville, Arkansas, USA.
FAU - Geels, Caroline
AU  - Geels C
AD  - College of Medicine, University of Arkansas for Medical Sciences Northwest, 
      Fayetteville, Arkansas, USA.
FAU - Newton, James
AU  - Newton J
AD  - Department of Infectious Disease, Infection Prevention, Control, and Treatment, 
      Washington Regional Medical Center, Fayetteville, Arkansas, USA.
LA  - eng
PT  - Journal Article
DEP - 20220803
PL  - United States
TA  - Monoclon Antib Immunodiagn Immunother
JT  - Monoclonal antibodies in immunodiagnosis and immunotherapy
JID - 101590955
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Drug Combinations)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Spike Glycoprotein, Coronavirus)
RN  - 0 (Viral Envelope Proteins)
RN  - 0 (casirivimab and imdevimab drug combination)
RN  - 0 (spike protein, SARS-CoV-2)
RN  - 2Z3DQD2JHM (imdevimab)
RN  - J0FI6WE1QN (casirivimab)
RN  - SARS-CoV-2 variants
SB  - IM
MH  - Antibodies, Monoclonal
MH  - Antibodies, Monoclonal, Humanized
MH  - Antibodies, Neutralizing
MH  - *COVID-19
MH  - Drug Combinations
MH  - Humans
MH  - Membrane Glycoproteins
MH  - Outpatients
MH  - Retrospective Studies
MH  - *SARS-CoV-2
MH  - Spike Glycoprotein, Coronavirus
MH  - Viral Envelope Proteins
OTO - NOTNLM
OT  - COVID-19
OT  - Regen-COV
OT  - SARS-CoV-2
OT  - casirivimab/imdevimab
OT  - subcutaneous monoclonal antibodies
EDAT- 2022/08/04 06:00
MHDA- 2022/08/31 06:00
CRDT- 2022/08/03 11:14
PHST- 2022/08/04 06:00 [pubmed]
PHST- 2022/08/31 06:00 [medline]
PHST- 2022/08/03 11:14 [entrez]
AID - 10.1089/mab.2022.0008 [doi]
PST - ppublish
SO  - Monoclon Antib Immunodiagn Immunother. 2022 Aug;41(4):210-213. doi: 
      10.1089/mab.2022.0008. Epub 2022 Aug 3.